The Growing Impact Of Oncotarget In The Medical World

Oncotarget is a free journal that has made a name for itself in the medical world. It was founded in 2010 and has significantly grown in terms of its impact. It is published by Impact Journals. The journal was measured by Thomson Reuters JCR to find out its impact factor. In 2011 Oncotarget was at 4.784 while in the year 2016/2017 it was at 5.168. There have also been increased citations from the journal proving its success. It has also been given the highest ranking by Scopus because of the positive contributions made.The main reason Oncotarget was started was to touch on oncology and the research that is being done in this particular area. The information given goes in depth. The opinion of patients in regards to different treatment methods is captured. This information is important to individuals who might be in the same condition as the patient.

After a number of trials, if the new procedure is considered worthwhile, it will be taken up. There are often different treatment methods that are discovered each day and various medical personnel need to know about them.The Official Website for the journal makes the material they publish more accessible. More people are online these days and sparing sometime to find out about their health is made easy because of the site. Each article that is published depends on what people want to know in that particular period. The publications are done on a weekly basis meaning content has to be planned in good time.

The journal is reviewed by other medics ensuring that the content that is posted is legit. The website has a section for reviews whereby individuals can talk about their experience and read about what others have to say.Time after time the journal keeps growing. It has been able to link researchers and other stakeholders in the medical field. Oncotarget has widened its scope from not only focusing on oncology but also other areas such as neurology, cardiology and pharmacology. Articles such as endocrinology and metabolism are also included. Focusing on many disciplines will see the journal becoming even more successful in the near future.

Mikhail Blagosklonny Extends His Research From Cancer To Aging Treatments

As one of the senior researchers at the Roswell Park Cancer Institute Mikhail Blagosklonny has been given a role that allows him to conduct research into various aspects of cancer treatments and anti-aging treatments at https://www.linkedin.com/in/mikhail-blagosklonny-91abb531 that have made him one of the best known names in the medical industry. The work of Mikhail Blagosklonny has taken many different forms over recent times, including the more than 170 article, chapters, and reviews the graduate of the First Pavlov State Medical University of Saint Peterburg has completed.

Over the course of his career Mikhail Blagosklonny has worked at some of the top cancer institutes and research centers in the U.S.; arriving at the Roswell Park Cancer Institute in 2009 the well known researcher was already well known for the role he has played as an impressive researcher in the treatments of cancer in many different forms. One of the areas of interest that has grown for Mikhail Blagosklonny in recent years has been his work in cancer and healthy cell treatments.

The work Mikhail Blagosklonny has completed in cancer treatments on impactjournals.com has not been limited to the treatment and protection of healthy cells, but has also evolved to include a range of treatment options designed to prolong life and reduce the effects of aging. The professor of Oncology at Roswell Park Institute has developed his own treatments to protect individuals from the effects of chemotherapy and other cancer treatments on Impactjournals.com as he has also looked to discover more about the ways the rapamycin drug can assist in slowing aging for people as they move through life; the work completed by Blagosklonny has been reported in some of the world’s top research journals to show how well respected he has become over the course of his career.